Tirzepatide appears to be relatively safer among the GLP-1 RAs, with a lower risk of gallbladder or biliary tract diseases (Tang et al., 2022; Mishra et al., 2023; Kamrul-Hasan et al., 2024). This evidence concerns the gene GCG and biliary tract disorder.